Indicators
Indicators
Value
Direction
MACD(12,26,9)
-0.008
Sell
RSI(14)
37.486
Neutral
STOCH(KDJ)(9,3,3)
36.047
Neutral
ATR(14)
0.049
High Vlolatility
CCI(14)
-108.891
Sell
Williams %R
69.891
Sell
TRIX(12,20)
-0.508
Sell
StochRSI(14)
0.000
Oversold
Search
Rockwell Medical Inc
RMTIAdd to Watchlist
0.792USD
-0.004-0.55%
Close 05/15, 16:00（ET）Quotes delayed by 15 min
31.26MMarket Cap
LossP/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of Rockwell Medical Inc
Currency: USD Updated: 2026-05-15Key Insights
Rockwell Medical Inc's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 73 out of 155 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 3.00.In the medium term, the stock price is expected to trend down.Despite a very weak market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Rockwell Medical Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Rockwell Medical Inc Highlights
StrengthsRisks
Rockwell Medical, Inc. is a healthcare company. The Company develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products for dialysis providers worldwide. The Company operates in the hemodialysis market, which involves the manufacture, sale and distribution of hemodialysis products to hemodialysis clinics, including pharmaceuticals, dialysis concentrates, dialysis kits and other ancillary products used in the dialysis process. Its hemodialysis concentrates products are used to sustain a patient's life by removing toxins and balancing electrolytes in a dialysis patient’s bloodstream. The Company is the supplier of liquid and dry, acid and bicarbonate concentrates for dialysis patients in the United States. The Company manufactures hemodialysis concentrates at its facilities in Michigan, South Carolina, and Texas, and the Company manufactures its dry acid concentrate mixers at its facility in Iowa.
Growing
The company is in a growing phase, with the latest annual income totaling USD 69.26M.
Fairly Valued
The company’s latest PE is -5.34, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 5.15M shares, decreasing 29.95% quarter-over-quarter.
Held by James Simons
Star Investor James Simons holds 468.32K shares of this stock.
Analyst Rating
Based on
2
analysts
Buy
Current Rating
3.000
Target Price
+276.65%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Financial Health
Currency: USD Updated: 2026-05-15The current financial score of Rockwell Medical Inc is 7.91, ranking 78 out of 155 in the Pharmaceuticals industry. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 17.34M, representing a year-over-year decrease of 8.34%, while its net profit experienced a year-over-year decrease of 5.94%.
Score
Financials
7.24
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
7.48
Operational Efficiency
10.00
Growth Potential
7.56
Shareholder Returns
7.26
Rockwell Medical Inc's Company Valuation
Currency: USD Updated: 2026-05-15The current valuation score of Rockwell Medical Inc is 8.71, ranking 8 out of 155 in the Pharmaceuticals industry. Its current P/E ratio is -5.34, which is -89.82% below the recent high of -0.54 and -26986.81% above the recent low of -1447.06.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 73/155
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2026-05-15The current earnings forecast score of Rockwell Medical Inc is 8.00, ranking 58 out of 155 in the Pharmaceuticals industry. The average price target is 3.75, with a high of 5.00 and a low of 2.50.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
2
analysts
Buy
Current Rating
3.000
Target Price
+276.65%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
174
Total
6
Median
8
Average
Company name
Ratings
Analysts
Rockwell Medical Inc
RMTI
2
Amgen Inc
AMGN
38
Biogen Inc
BIIB
37
Eli Lilly and Co
LLY
35
AbbVie Inc
ABBV
34
Vertex Pharmaceuticals Inc
VRTX
33
1
2
3
...
35
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2026-05-15The current price momentum score of Rockwell Medical Inc is 6.27, ranking 119 out of 155 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 0.91 and the support level at 0.71, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
0.814
Sell
MA10
0.825
Sell
MA20
0.852
Sell
MA50
0.907
Sell
MA100
0.948
Sell
MA200
1.050
Sell
Institutional Confidence
Currency: USD Updated: 2026-05-15The current institutional shareholding score of Rockwell Medical Inc is 3.00, ranking 94 out of 155 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 13.04%, representing a quarter-over-quarter increase of 51.97%. The largest institutional shareholder is James Simons, holding a total of 639.12K shares, representing 1.62% of shares outstanding, with 22.16% increase in holdings.
Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Shareholder Activity
Name
Shares Held
Chg %
Irrevocable Larson Family Investment Trust
Geode Capital Management, L.L.C.
BlackRock Institutional Trust Company, N.A.
UBS Financial Services, Inc.
Ravich (Mark H)
Cooper (John G)
1
2
Risk Assessment
Currency: USD Updated: 2026-05-15The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Pharmaceuticals domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Rockwell Medical Inc is 2.80, ranking 116 out of 155 in the Pharmaceuticals industry. The company's beta value is 1.63. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.
Score
Beta vs S&P 500 index
1.62
VaR
+7.10%
240-Day Maximum Drawdown
+57.32%
240-Day Volatility
+96.26%
Return
Best Daily Return
60 days
+10.96%
120 days
+31.62%
5 years
+31.62%
Worst Daily Return
60 days
-9.41%
120 days
-9.41%
5 years
-39.14%
Sharpe Ratio
60 days
-1.79
120 days
+0.14
5 years
-0.10
Risk Assessment
Maximum Drawdown
240 days
+57.32%
3 years
+87.38%
5 years
+90.06%
Return-to-Drawdown Ratio
240 days
-0.36
3 years
-0.33
5 years
-0.20
Skewness
240 days
+1.95
3 years
+0.37
5 years
+0.45
Volatility
Realised Volatility
240 days
+96.26%
5 years
+105.52%
Standardised True Range
240 days
+10.26%
5 years
+25.14%
Downside Risk-Adjusted Return
120 days
+28.45%
240 days
+28.45%
Maximum Daily Upside Volatility
60 days
+45.50%
Maximum Daily Downside Volatility
60 days
+42.05%
Liquidity
Average Turnover Rate
60 days
+0.75%
120 days
+1.35%
5 years
--
Turnover Deviation
20 days
-55.28%
60 days
-55.59%
120 days
-20.41%
Peer Comparison
Pharmaceuticals
Rockwell Medical Inc
RMTI
6.72 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Catalyst Pharmaceuticals Inc
CPRX
9.11 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Jazz Pharmaceuticals PLC
JAZZ
8.81 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Royalty Pharma PLC
RPRX
8.72 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Kiniksa Pharmaceuticals International PLC
KNSA
8.59 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Neurocrine Biosciences Inc
NBIX
8.52 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
